ACTU logo

ACTUATE THERAPEUTICS INC

ACTUNASDAQ
🏆 #4667 by market capEarnings Mar 26US Equity
$0.23▲ $0.01 (+5.38%)
Market closed · at close
🔔
Track ACTU
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 5.4%
7d▼ 21.6%
14d▼ 28.6%
30d▼ 51.7%
ytd▼ 96.3%
1y▼ 96.4%
🏦Market Cap
$12M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$0.20 – $0.25
52-Week Range
$0.17 – $7.90
Volume (shares)
646,643
Avg Volume (shares)
—
Shares Outstanding
55.0M
Next Earnings
2027-03-26

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
$-0.89
Dividend Yield
—
Dilution (1yr)
+19.1%
ACTU logo

ACTUATE THERAPEUTICS INC

ACTU
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$22M▼ −10.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$19M▼ −12.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
23.2M▲ +19.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$13M▲ +$4M YoY
StockOtter · stockotter.space

About ACTUATE THERAPEUTICS INC

Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

GlobeNewsWire·4d ago

Actuate Therapeutics Reports Positive Monotherapy Data in Aggressive Melanoma Preclinical Model with Daily Dosing of Elraglusib Oral Tablet at ENA 2026

Daily oral elraglusib achieved up to 77% tumor growth inhibition as monotherapy in an aggressive preclinical melanoma model, with greater antitumor activity observed at higher drug exposures Treatment was associated with

GlobeNewsWire·18d ago

Actuate Therapeutics to Present Promising Preclinical Data Demonstrating Antitumor and Immune Activation Activity of Elraglusib Oral Tablet in Advanced Melanoma Models at ENA 2026

-     Oral tablet formulation of elraglusib as a monotherapy significantly inhibited tumor growth and       enhanced antitumor immune activity in an aggressive, poorly immunogenic melanoma model -     Phase 1/2 clinical

GlobeNewsWire·20d ago

Actuate Therapeutics Receives U.S. Notice of Allowance for Patent Covering Elraglusib Oral Tablets

Oral tablet form expected to allow Company to optimize patient plasma exposure levels  with convenient daily dosing of drug

GlobeNewsWire·26d ago

Actuate Therapeutics Announces Pricing of $11.0 Million Underwritten Public Offering

CHICAGO and FORT WORTH, Texas, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapies fo

GlobeNewsWire·Sep 9

Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference

CHICAGO and FORT WORTH, Texas, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for th

GlobeNewsWire·Sep 9

Actuate Announces Promising Preclinical Data Showing Synergistic Activity of Elraglusib in Combination with RAS Inhibitors Zoldonrasib and Daraxonrasib

CHICAGO and FORT WORTH, Texas, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing novel therapies